ArticleThe Lancet regional health. Europe2026
Childhood cancer incidence by migrant background in Sweden (1991-2021): a nationwide cohort study.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies indicate that incidence of certain childhood cancers is lower in low-compared to high-income countries. By examining incidence in migrant populations in Sweden, we aimed to disentangle whether this is due to methodological factors, such as underreporting, or to genetic or environmental aetiology. Methods: In this nationwide, population-based cohort study, we grouped all children born in Sweden (1990-2019) as: Swedish background, 2nd generation, 2.5 generation (one foreign-born, one Swedish-born parent), or 3rd generation. Age-standardized incidence rates (ASR) for first childhood cancer identified in the National Cancer Register (ages 1-19) were calculated using the 2013 European standard population and are reported per 100,000 person-years [95% confidence intervals]. Incidence rate ratios (IRR) were calculated using Poisson regression adjusted for year of birth and sex. Using the same methods, we examined childhood cancer incidence by parental lineages separately, parental length of stay before birth, and World Bank income classification of parental country of birth. Findings: During 39,862,393 person-years of follow-up, 6797 children were diagnosed with cancer. The ASR of childhood cancer in Swedish background children was 17.18 [16.63-17.74], this was slightly higher in boys (18.20 [17.42-19.01]) than girls (16.09 [15.34-16.88]). The overall results were largely similar across migrant generations and parental length of stay. Lymphoma incidence was higher in 2nd generation (ASR 3.09 [2.53-3.78]) compared to Swedish background children (2.22 [2.02-2.44]). Children with migrant mothers from high-income countries had a higher incidence of leukaemia (ASR 5.88 [4.78-7.24]) compared to Swedish background children (4.31 [4.09-4.55]), whereas central nervous system tumour and leukaemia incidence was lower in children with mothers from low-income countries (2.64 [1.79-3.88], 3.66 [2.76-4.85], respectively) compared to Swedish background children (4.49 [4.24-4.75], (4.31 [4.09-4.55]). The pattern was similar for fathers from low-income countries and for IRRs. Interpretation: Finding lower incidence of CNS tumours and leukaemia among children born in Sweden to mothers from low-income countries challenges the hypothesis that low incidence of some childhood cancers in low-income countries is solely due to underreporting, but rather suggest that genetic or environmental factors may underlie these observations. Funding: Barncancerfonden (PR2023-0060).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.